Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity

Stephen Hanessian; Ramkrishna Reddy Vakiti; Amit Kumar Chattopadhyay; Stéphane Dorich; Christian Lavallée

doi:10.1016/j.bmc.2013.01.037

Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity

Bioorg Med Chem. 2013 Apr 1;21(7):1775-86. doi: 10.1016/j.bmc.2013.01.037. Epub 2013 Jan 31.

Authors

Stephen Hanessian¹, Ramkrishna Reddy Vakiti, Amit Kumar Chattopadhyay, Stéphane Dorich, Christian Lavallée

Affiliation

¹ Department of Chemistry, Université de Montréal, Station Centre Ville, CP 6128, Montréal, Qc, Canada H3C 3J7. stephen.hanessian@umontreal.ca

PMID: 23434136
DOI: 10.1016/j.bmc.2013.01.037

Abstract

A total of eight new analogs of pactamycin were prepared and tested alongside pactamycin and three of its natural congeners for antibacterial, anticancer, and antiprotozoal activities. The present study highlights the effects of changing the urea and aniline groups especially with regard to anticancer and antiprotozoal activities.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / chemistry*
Anti-Bacterial Agents / pharmacology
Antineoplastic Agents / chemistry*
Antineoplastic Agents / pharmacology
Antiprotozoal Agents / chemistry*
Antiprotozoal Agents / pharmacology
Bacteria / drug effects
Bacterial Infections / drug therapy
Cell Line, Tumor
Humans
Malaria, Falciparum / drug therapy
Neoplasms / drug therapy
Pactamycin / analogs & derivatives*
Pactamycin / pharmacology
Plasmodium falciparum / drug effects

Substances

Anti-Bacterial Agents
Antineoplastic Agents
Antiprotozoal Agents
Pactamycin